November 18, 2026
Health news, explained with evidence
LIVE

Recent Trials Spark Debate Over Perioperative Immunotherapy in Bladder Cancer

❤️ Conditions & Care 1 min read 👁 1

Oncology experts discuss mixed findings from recent clinical trials investigating the addition of immune checkpoint inhibitors to chemotherapy for muscle-invasive bladder cancer.

Recent Trials Spark Debate Over Perioperative Immunotherapy in Bladder Cancer❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • KEYNOTE-866 and ENERGIZE trials showed mixed results for chemo-immunotherapy combinations.
  • Findings contrasted with the earlier positive NIAGARA trial outcomes.
  • Experts emphasize that newer antibody-drug conjugate regimens are shifting clinical standards.

Specialists in bladder cancer care have reviewed recent findings from the KEYNOTE-866 and ENERGIZE trials, which were presented at the European Society for Medical Oncology congress. The panel, featuring prominent oncologists from major cancer centers, evaluated how these outcomes contrast with earlier positive data from the NIAGARA trial regarding perioperative treatment approaches for muscle-invasive bladder cancer.

While the trials demonstrated some improvements in pathologic complete response rates compared to control arms, they did not show corresponding enhancements in event-free survival or overall survival. Experts noted that differing trial eras, patient populations, and shifting treatment landscapes make direct comparisons challenging. For instance, the ENERGIZE trial included a high percentage of patients with clinical T2 disease, potentially representing a lower-risk cohort.

Although the studies raise important scientific questions about combining immunotherapy with cisplatin-based regimens, specialists suggest that newer data involving antibody-drug conjugates combined with immunotherapy are increasingly forming the backbone of current perioperative strategies. As clinical practices evolve, patients are advised to consult their physicians for personal medical guidance and tailored treatment decisions.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/esmoexpertroundtable/123924 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.